Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03528642 · ClinicalTrials.gov registry record · Phase 1
Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma
A Phase 1 study of Astrocytoma, IDH-Mutant, Grade 2 and Astrocytoma, IDH-Mutant, Grade 3, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
- 20
- Study locations
NCT03528642 is a Phase 1 study of Astrocytoma, IDH-Mutant, Grade 2 and Astrocytoma, IDH-Mutant, Grade 3 that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 40 participants. The trial reports 20 study locations across 12 states.
The verdict
NCT03528642, a Phase 1 study of Astrocytoma, IDH-Mutant, Grade 2 and Astrocytoma, IDH-Mutant, Grade 3, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
- 20
- Study locations
Study Summary
This phase 1b trial studies the side effects and best dose of telaglenastat in combination with radiation therapy and temozolomide in treating patients with IDH-mutated diffuse or anaplastic astrocytoma. Telaglenastat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Chemotherapy drugs, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving telaglenastat with radiation therapy and temozolomide may work better than surgery, radiation therapy, and temozolomide in treating patients with IDH-mutated diffuse astrocytoma or anaplastic astrocytoma.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- RADIATION Radiation Therapy
- DRUG Temozolomide
- DRUG Telaglenastat Hydrochloride
Study Locations (20)
Missouri
- Siteman Cancer Center at Saint Peters Hospital - City of Saint Peters
- Siteman Cancer Center at West County Hospital - Creve Coeur
- Washington University School of Medicine - St Louis
- Siteman Cancer Center-South County - St Louis
- Siteman Cancer Center at Christian Hospital - St Louis
Arizona
- Mayo Clinic Hospital in Arizona - Phoenix
- Mayo Clinic in Arizona - Scottsdale
California
- UC San Diego Moores Cancer Center - La Jolla
- UC Irvine Health/Chao Family Comprehensive Cancer Center - Orange
Florida
- Mayo Clinic in Florida - Jacksonville
- Moffitt Cancer Center - Tampa
New York
- Laura and Isaac Perlmutter Cancer Center at NYU Langone - New York
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center - New York
District of Columbia
- Sibley Memorial Hospital - Washington D.C.
Iowa
- University of Iowa/Holden Comprehensive Cancer Center - Iowa City
Kentucky
- University of Kentucky/Markey Cancer Center - Lexington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2019-05-01 |
| Est. Completion | 2026-05-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03528642
The ClinicalTrials.gov registry entry for NCT03528642 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Astrocytoma, IDH-Mutant, Grade 2 appearing as the primary indexed condition, and to 4 interventions - of which Questionnaire Administration is the first listed.
NCT03528642 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Missouri, Arizona, California.
Frequently Asked Questions
What is clinical trial NCT03528642 about?
NCT03528642 is a clinical study titled "Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma". This phase 1b trial studies the side effects and best dose of telaglenastat in combination with radiation therapy and temozolomide in treating patients with IDH-mutated diffuse or anaplastic astrocytoma. Telaglenastat may stop the growth of tumor cells by blocking some of the enzymes needed for cell...
What is the current status of trial NCT03528642?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2019-05-01. Estimated completion is 2026-05-08.
What conditions does trial NCT03528642 study?
This clinical trial studies the following conditions: Astrocytoma, IDH-Mutant, Grade 2, Astrocytoma, IDH-Mutant, Grade 3.
What interventions are being tested in trial NCT03528642?
The interventions under investigation include: Questionnaire Administration (OTHER), Radiation Therapy (RADIATION), Temozolomide (DRUG), Telaglenastat Hydrochloride (DRUG).
Who is sponsoring clinical trial NCT03528642?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03528642 being conducted?
This trial has 20 study locations across Arizona, California, District of Columbia, Florida, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Astrocytoma, IDH-Mutant, Grade 2
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Astrocytoma, IDH-Mutant, Grade 2
All registered trials for this condition
Astrocytoma, IDH-Mutant, Grade 3
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.